Drug Profile
Felezonexor - Stemline Therapeutics
Alternative Names: CBS 9106; SL-801Latest Information Update: 28 Apr 2022
Price :
$50
*
At a glance
- Originator CanBas
- Developer Stemline Therapeutics
- Class Antineoplastics; Fluorocarbons; Pyridines; Pyrrolidinones; Small molecules
- Mechanism of Action Exportin-1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
- No development reported Haematological malignancies
Most Recent Events
- 28 Apr 2022 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO, Tablet)
- 27 Jan 2022 Stemline Therapeutics completes a phase I trials in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in USA (PO) (NCT02667873)
- 28 May 2021 No recent reports of development identified for preclinical development in Haematological-malignancies(Combination therapy) in USA (PO)